

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
WO 2004/005343 A1

(51) International Patent Classification<sup>7</sup>: C07K 14/59

(21) International Application Number:  
PCT/KR2003/001308

(22) International Filing Date: 2 July 2003 (02.07.2003)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:  
10-2002-0038064 2 July 2002 (02.07.2002) KR

(71) Applicant (for all designated States except US): NEX-  
GEN BIOTECHNOLOGIES, INC. [KR/KR]; 2Fl.  
Yurim Bldg., 65-1, Wonchon-dong, Yusung-gu, Daejeon  
Metropolitan City 305-370 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHONG,  
Min-Ho [KR/KR]; 108-1501 Purunmoe Apartment,  
Taepyung-dong, Jung-gu, Daejeon Metropolitan City  
301-150 (KR). LEE, Sun [KR/KR]; 108-703 Se-  
jong Apartment, Jeonmin-dong, Yusung-gu, Daejeon  
Metropolitan City 305-390 (KR). YOO, Jae-Geun

[KR/KR]; 112-301 Hansup Apartment, Yongjeon-dong,  
dong-gu, Daejeon Metropolitan City 300-768 (KR). JIN,  
Seok-Min [KR/KR]; 112-1402 Chunggu Apartment, Han-  
sol Maeul, 110, Jeongja-dong, Bundang-gu, Seongnam-si,  
Gyeonggi-do 463-833 (KR).


(74) Agent: SESHIN PATENT & LAW FIRM; 8th Fl.,  
KFSB Bldg., 16-2 Yeodo-dong, Yeongdeungpo-gu, Seoul  
150-010 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PRODUCTION OF TRANSFORMED PLANTS EXPRESSING THYROID STIMULATING HORMONE RECEPTOR



1 : TSHR expressed in CHO cell line  
2 : Wild type *Nicotiana tabacum*  
3-4 : TSHR expressed in the transformed  
*Nicotiana tabacum*

(57) Abstract: The present invention relates to a method for preparing transformed plants expressing thyroid stimulating hormone receptor. In particular, the present invention relates to a method for preparing transformed plants expressing (hTSHR) or (hTSHR-ECD) which comprises the steps of: (a) transforming plant cells with the following polynucleotide sequences: (i) a polynucleotide sequence encoding hTSHR or hTSHR-ECD; (ii) a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the polynucleotide sequence of (i); and (iii) a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of said RNA molecule; (b) selecting transformed plant cells; and (c) obtaining transformed plant by regenerating said transformed plant cells, transformed plants and a method for preparing hTSHR or hTSHR-ECD.

WO 2004/005343 A1

WO 04/005343 A1



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**PRODUCTION OF TRANSFORMED PLANTS EXPRESSING THYROID STIMULATING  
HORMONE RECEPTOR**

**FIELD OF THE INVENTION**

5       The present invention relates to a method for preparing transformed plants expressing thyroid stimulating hormone receptor. In particular, the present invention relates to a method for preparing transformed plants expressing thyroid stimulating hormone receptor (hTSHR) or thyroid stimulating hormone receptor-  
10 extracellular domain (hTSHR-ECD), transformed plants, and a method for preparing hTSHR or hTSHR-ECD.

**DESCRIPTION OF THE RELATED ART**

15       Molecular farming is a technique producing recombinant proteins in plants. Recently, in the developed countries, the studies on the medical application of molecular farming have been performed. On account of the fact that recombinant proteins are extensively used as therapeutic agents of various diseases, it is expected that molecular farming may be an advantageous technique providing  
20 highly valuable and safe recombinant proteins.

      Medical proteins prepared from transformed animals have a problem in long-term safety due to the risk of zoonosis such as Mad Cow Disease and are not much profitable considering the production cost. Furthermore, when prokaryotic expression system  
25 is used for producing medical proteins, proteins are not subject to a secondary modification and result in no therapeutic effect.

However, recombinant proteins obtained from plants by using molecular farming technique have no risk of zoonosis, are able to be conveniently prepared in large amount, and are suitably secondary-modified to treat diseases promisingly. Such useful proteins can be provided economically through molecular farming.

Ten% of world population suffers from various autoimmune diseases such as rheumatoid arthritis, autoimmune thyroid disease, multiple sclerosis, insulin dependent diabetes mellitus, and autoimmune skin disease. As there are no known ways to treat autoimmune diseases radically, symptomatic treatment which cures diseases according to symptom and immune suppression therapy over long term are generally employed.

It is expected that oral tolerance suppressing autoimmune reaction by induction of immunological tolerance through nasal oral or cavity administration of autoantigen may be applicable to treatment of human autoimmune disease after animal test in several years for treating and preventing such autoimmune disease (U.S. Pat. No. 5,733,547).

A technical problem to be solved for clinical application of oral tolerance is how to obtain efficiently a large amount of autoantigen to be used in treatment. That is because the essential feature of oral tolerance is to administer high-dose of autoantigen through oral or nasal cavity, which is inevitably required.

**DETAILED DESCRIPTION OF THIS INVENTION**

The present inventors have made attempts to develop a novel system which provides a large amount of thyroid stimulating hormone receptor (hTSHR) elucidated as a human autoantigen. As a result, the present inventors have prepared plants transformed with hTSHR or hTSHR-ECD gene successfully and found that hTSHR or hTSHR-ECD produced from transformants has high antigenicity.

Accordingly, it is an object of this invention to provide a method for preparing transformed plants expressing hTSHR or hTSHR-ECD.

It is another object of this invention to provide transformed plants.

It is still another object of this invention to provide a method for preparing hTSHR or hTSHR-ECD.

In one aspect of this invention, there is provided a method for preparing transformed plants expressing thyroid stimulating hormone receptor (hTSHR) or thyroid stimulating hormone receptor-extracellular domain (hTSHR-ECD), which comprises the steps of:

(a) transforming plant cells with the following polynucleotide sequences: (i) a polynucleotide sequence encoding hTSHR or hTSHR-ECD; (ii) a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the polynucleotide sequence of (i); and (iii) a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of said RNA molecule;

(b) selecting transformed plant cells; and

(c) obtaining transformed plant by regenerating said transformed plant cells.

In another aspect of this invention, there is provided a  
5 transformed plant which is prepared by the above method and expresses hTSHR or hTHSR-ECD.

According to this invention, plants transformed with a full length gene of autoantigen or its portion which involves in  
10 autoimmune thyroid disease are prepared and from them, a large amount of human thyroid stimulating hormone receptor (hTSHR), a representative human autoantigen, are provided for diagnosis and treatment.

A human autoantigen, hTSHR, has been proved to be an  
15 autoantigen causing hyperthyroidism. The antibody against hTHSR stimulates thyroid stimulating hormone receptor expressed on cell membrane of thyroid, which in turn increases the production of thyroid hormone and hyperthyroidism is finally developed, like the case of thyroid stimulating hormone. Therefore, the detection of  
20 IgG antibody against hTSHR could be applied to diagnosis of hyperthyroidism, and the mass production of hTSHR would enable hTSHR to be used in oral tolerance therapy.

hTSHR antibody found in patients is known not to bind to recombinant protein expressed in prokaryotic expression system, so  
25 that hTSHR prepared from *E. coli* is useless for detecting IgG of patients. This suggests that hTSHR expressed in prokaryote requires secondary modification such as glycosylation to function

as an immunogen. Consequently, a eucaryotic expression system should be employed for the application of hTSHR as diagnostic antigen or to oral tolerance therapy. In addition, it is found that hTSHR expressed in an expression system derived from vaccinia virus is not valuable because of low binding affinity to antibody.

The present method for preparing human autoantigen from transformed plants is directed to the mass production of human proteins in plant and could be a pivotal technology for the next generation-drug development (particularly, for producing human autoantigen used in the treatment of autoimmune disease).

In the present invention, hTSHR or hTSHR-ECD corresponding to the extracellular domain of intact hTSHR is used. hTSHR-ECD is a significant region for hTSHR to function as antigen (GS Seetharamaiah, et al., Requirement of glycosylation of the human thyrotropin receptor ectodomain for its reactivity with autoantibodies in patients' sera, *J. Immunol.*, 158:2798-2804(1997)).

The nucleotide sequence of hTSHR or hTSHR-ECD used herein includes the sequences known in the art as well as modified suitably for expression in plant cell. The exemplified hTSHR nucleotide sequence used in the present invention is set forth in SEQ ID NO:1 and the exemplified hTSHR-ECD nucleotide sequence corresponds to the polynucleotide spanning nucleotide 1-1254 of SEQ ID NO:1 which encodes the amino acid sequence 1-418 of SEQ ID NO:2. The modification of the nucleotide sequence for efficient expression in plants can be achieved by various manipulations such

as adjusting GC content, introducing proper codon usage preferred in plant and removing intron-like sequence (Kusnadi et al., Biotechnol. Bioeng. 56:473-484(1997); and WO 9116432).

According to a preferred embodiment, promoters used conventionally for transformation of plant in the art may be used, including the cauliflower mosaic virus (CaMV) 35S promoter, nopaline synthase (nos) promoter, the Figwort mosaic virus 35S promoter, the sugarcane bacilliform virus promoter, the commelina yellow mottle virus promoter, the light-inducible promoter from the small subunit of the ribulose-1,5-bis-phosphate carboxylase (ssRUBISCO), the rice cytosolic triosephosphate isomerase (TPI) promoter, the adenine phosphoribosyltransferase (APRT) promoter of Arabidopsis, the rice actin 1 gene promoter, and the mannopine synthase and octopine synthase promoters.

The 3'-non-translated region suitable in this invention may include that from the nopaline synthase gene of *Agrobacterium tumefaciens* (nos 3' end) (Bevan et al., *Nucleic Acids Research*, 11(2):369-385(1983)), that from the octopine synthase gene of *Agrobacterium tumefaciens*, the 3'-end of the protease inhibitor I or II genes from potato or tomato, the CaMV 35S terminator.

The transformation of plant cells may be carried out according to the conventional methods known one of skill in the art, including electroporation (Neumann, E. et al., *EMBO J.*, 1:841(1982)), particle bombardment (Yang et al., *Proc. Natl. Acad. Sci.*, 87:9568-9572(1990)) and *Agrobacterium*-mediated transformation (U.S. Pat. Nos. 5,004,863, 5,349,124 and 5,416,011). Among them, *Agrobacterium*-mediated transformation is the most preferable. *Agrobacterium*-mediated transformation is generally performed with leaf disks and other tissues such as cotyledons and

hypocotyls. This method is the most efficient in dicotyledonous plants.

The selection of transformed cells may be carried out with exposing the transformed cultures to a selective agent such as a metabolic inhibitor, an antibiotic and herbicide. Cells which have been transformed and have stably integrated a marker gene conferring resistance to the selective agent will grow and divide in culture. The exemplary marker includes, but not limited to, a glyphosphate resistance gene and a neomycin phosphotransferase (nptII) system.

The development or regeneration of plants from either plant protoplasts or various explants is well known in the art. The resulting transgenic rooted shoots are planted in an appropriate plant growth medium. The development or regeneration of plants containing the foreign gene of interest introduced by *Agrobacterium* may be achieved by methods well known in the art (U.S. Pat. Nos. 5,004,863, 5,349,124 and 5,416,011).

Meanwhile, the present inventors have made attempts to develop novel transformed plants such as *Nicotiana tabacum*, *Cucumis melo*, *Curcumis sativa*, *Citrullus vulgaris* and *Brassica campestris* and as a result, have established the most efficient methods for the transformation of certain plant. Such methods have been filed for patent application (PCT/KR02/01461, PCT/KR02/01462 and PCT/KR02/01463) which is incorporated herein by reference.

The method of the present invention is applicable to various plants, preferably, *Nicotiana tabacum*, *Cucumis melo*, *Curcumis sativa*, *Citrullus vulgaris* and *Brassica campestris*.

In the present invention, it is preferred to use *Agrobacterium* system for transformation, more preferably, *Agrobacterium*

*tumefaciens*-binary vector system.

The example of this invention employing *Agrobacterium* transformation system comprises the steps of: (a') inoculating an explant material from the plant with *Agrobacterium tumefaciens* harboring a vector, which is capable of inserting into a genome of a cell from the plant and contains the following nucleotide sequences: (i) a polynucleotide sequence encoding hTSHR or hTSHR-ECD; (ii) a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the polynucleotide sequence of (i); and (iii) a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of said RNA molecule; (b') regenerating the inoculated explant material on a regeneration medium to obtain regenerated shoots; (c') culturing the regenerated shoots on a rooting medium to obtain a transformed plant.

In the example, the explant for transformation includes any tissue derived from seed germinated. It is preferred to use cotyledon and hypocotyl and the most preferred is cotyledon. Seed germination may be performed under suitable dark/light conditions using an appropriate medium. Transformation of plant cells derived is carried out with *Agrobacterium tumefaciens* harboring Ti plasmid (Depicker, A. et al., Plant cell transformation by *Agrobacterium* plasmids. In Genetic Engineering of Plants, Plenum Press, New York (1983)).

More preferably, binary vector system such as pBin19, pRD400 and pRD320 is used for transformation (An, G. et al., Binary

vectors" In Plant Gene Res. Manual, Martinus Nijhoff Publisher, New York(1986)). The binary vector useful in this invention carries: (i) a promoter capable of operating in plant cell; (ii) a structural gene operably linked to the promoter; and (iii) a polyadenylation signal sequence. The vector may alternatively further carry a gene coding for reporter molecule (for example, luciferase and  $\beta$ -glucuronidase). Examples of the promoter used in the binary vector include but not limited to cauliflower mosaic Virus 35S promoter, 1' promoter, 2' promoter and promoter nopaline synthetase (nos) promoter.

Inoculation of the explant with *Agrobacterium tumefaciens* involves procedures known in the art. Most preferably, the inoculation involves immersing the cotyledon in the culture of *Agrobacterium tumefaciens* to coculture. *Agrobacterium tumefaciens* is infected into plant cells.

The explant transformed with *Agrobacterium tumefaciens* is regenerated in a regeneration medium, which allows successfully the regeneration of shoots. The transformed plant is finally produced on a rooting medium by rooting of regenerated shoots.

The transformed plant produced according to the present invention may be confirmed using procedures known in the art. For example, using DNA sample from tissues of the transformed plant, PCR is carried out to elucidate exogenous gene incorporated into a genome of the transformed plant. Alternatively, Northern or Southern Blotting may be performed for confirming the transformation (Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.(1989)).

According to a preferred embodiment, the step of recovering hTSHR or hTHSR-ECD from transformed plants is further included. hTSHR or hTHSR-ECD may be provided from the tissues derived from various transformed organs (e.g., stem, leave, root, fruit and seed, etc) and be obtained by purifying the extracts of the tissues.

In this invention, purification methods conventionally used in the art may be employed. For example, various methods including solubility fractionation by use of ammonium sulfate or PEG, size differential filtration and column chromatography (based on size, net surface charge, hydrophobicity or affinity) are available and usually the combination of the methods is used for purification.

Therefore, according to another embodiment, this invention provides a method for preparing thyroid stimulating hormone receptor (hTSHR) or thyroid stimulating hormone receptor-extracellular domain (hTSHR-ECD), which comprises the steps of: (a) transforming plant cells with the following polynucleotide sequences: (i) a polynucleotide sequence encoding hTSHR or hTSHR-ECD; (ii) a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the polynucleotide sequence of (i); and (iii) a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of said RNA molecule; (b) selecting transformed plant cells; (c) obtaining transformed plant by regenerating said transformed plant cells; and (d) recovering hTSHR or hTHSR-ECD from said transformed plant.

At present, the molecular farming with transformed plants and edible vaccines is considered plausible as technologies to provide novel therapeutic agents.

5 As this invention employs a eucaryote-expression system, the final products, hTHSR or hTHSR-ECD, are very likely to be secondarily modified (e.g., high antigenicity) and the convenient cultivation of transformed plants will allow to provide the mass production of human autoantigen, hTHSR or hTHSR-ECD. It could be  
10 appreciated that hTHSR or hTHSR-ECD prepared by this invention is applicable to oral tolerance therapy.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a plant-expressing cassette of human thyroid  
15 stimulating hormone receptor gene (*tshr*);

Fig. 2 shows a plant-expressing cassette of thyroid stimulating hormone receptor-extracellular domain gene (*tshr-ecd*);

Fig. 3 shows the *tshr* or *tshr-ecd* gene cloned in plant-transformation vector *pRD400*;

20 Fig. 4 is a photograph showing the PCR result of the transformed *tshr* gene in plants transformed with *tshr*;

Fig. 5 is a photograph showing the PCR result of the transformed *tshr-ecd* gene in plants transformed with *tshr-ecd*;

Fig. 6 is a photograph showing the result of Western Blotting  
25 demonstrating the expression of TSHR in transformed plants; and

Fig. 7 is a photograph showing the result of ELISA analysis of TSHR produced in transformed plants using IgGs obtained from Grave's disease patient.

The following specific examples are intended to be illustrative of the invention and should not be construed as limiting the scope of the invention as defined by appended claims.

5

**EXAMPLES****EXAMPLE I: Cloning of *tshr* Gene**

From the known human *tshr* cDNA information registered in GenBank (<http://www.ncbi.nlm.nih.gov/>) (XM-056624, XM-041159, XM-041157, M73747 and BC009237), cDNA nucleotide sequence was  
10 obtained. The full length of human *tshr* gene was amplified by RT-PCR and cloned into TA vector. The insertion of the human *tshr* gene was then confirmed by sequencing.

15 i) Cloning of full length of *tshr* gene

Firstly, a pair of primers designed on the basis of the nucleotide sequence of *tshr* gene searched in GenBank database was synthesized for PCR in order to subclone the full length of *tshr* gene (about 2.3 kb) into the plant-expression cassette of a vector.  
20 The primer for 5'-flanking region was designed to have a start codon of *tshr* gene and *Bam*HI recognition site for cloning into cassette (5'-AAGGATCCC ATG AGG CCG GCG GAC-3'), and the primer for 3'-flanking region was designed to include a stop codon and *Bam*HI recognition site for cloning into cassette (5'-ATGGATCC TTA CAA  
25 AAC CGT TTG CAT-3').

25  $\mu$ l of PCR mixture was prepared containing 1.25 unit Taq DNA polymerase (Boehringer Mannheim), 2.5  $\mu$ l of 10x buffer (Boehringer

Mannheim), 2  $\mu$ l of 2.5 mM dNTP, 0.25  $\mu$ l of 100 pM primers and 50 ng of DNA including *tshr* gene. The PCR was conducted under the following conditions: pre-denaturation at 95°C for 2 min followed by 30 cycles of annealing at 55°C for 1 min, extension at 72°C for 1 min and denaturation at 92°C for 1 min; followed by final extension at 72°C for 10 min. The amplified products were kept at 4°C for analysis and electrophoresed on 0.8% TAE agarose gel.

The *tshr* gene was eluted and obtained from the corresponding band. In amplified DNA, *tshr* gene has the nucleotide sequence as set forth in SEQ ID No:1. The *tshr* gene fragment purified with glass milk was digested with suitable restriction enzymes and inserted into the binary vector pRD400 for plant transformation containing plant-expression cassette (Raju et al., Gene 211:383-384(1992)) digested with the same restriction enzymes. A cassette for plant expression of *tshr* gene in Fig. 1 was constructed.

#### ii) Cloning of portion of *tshr* gene

Firstly, a pair of primers designed on the basis of the nucleotide sequence of *tshr* gene searched in GenBank database was synthesized for PCR in order to subclone into the cassette of the plant-expression vector the gene (*tshr*-ecd, about 1.24 kb) that encodes an extracellular domain of TSHR displayed on the outside of human cells.

The primer for 5'-flanking region was designed to include a start codon of *tshr* gene and *Bam*HI recognition site for cloning into cassette (5'-AAGGATCCC ATG AGG CCG GCG GAC-3'), and the

primer for 3'-flanking region was designed to amplify a nucleotide sequence from start point of *tshr* gene to around nucleotide 1239 wherein the extracellular domain is encoded, and to have additional stop codon and *Bam*HI recognition site for cloning into cassette  
5 (5'-ATGGATCC TTA GCC CAT TAT GTC TTC-3').

25  $\mu$ l of PCR mixture was prepared containing 1.25 unit Taq DNA polymerase (Boehringer Mannheim), 2.5  $\mu$ l of 10x buffer (Boehringer Mannheim), 2  $\mu$ l of 2.5 mM dNTP, 0.25  $\mu$ l of 100 pM primers and 50 ng of DNA including *tshr-ecd*. The PCR was conducted under the  
10 following conditions: pre-denaturation at 95°C for 2 min followed by 30 cycles of annealing at 55°C for 1 min, extension at 72°C for 1 min and denaturation at 92°C for 1 min; followed by final extension at 72°C for 10 min. Amplified products were analyzed by electrophoresis on 0.8% TAE agarose gel at the constant  
15 temperature of 4°C. The desired *tshr* DNA fragment eluted and obtained from the corresponding band.

The *tshr-ecd* fragment purified with glass milk was digested with suitable restriction enzymes and inserted into binary vector pRD400 for plant transformation (Raju et al., Gene 211:383-  
20 384(1992) containing plant-expression cassette digested with the same restriction enzymes. A cassette for plant-expression of *tshr-ecd* in Fig. 2 was constructed.

#### EXAMPLE II: Transformation of Plant

##### 25 i) Infection of *Agrobacterium tumefaciens* GV3101

pRD400-*tshr* and pRD400-*tshr-ecd* (Fig. 3) of Example I obtained

by cloning into the binary vector for plant transformation, pRD400, was introduced respectively into *Agrobacterium tumefaciens* (*Agrobacterium tumefaciens* GV3101(mp90); *Plant-cell-rep.*, 15(11)799-803(1996)) by means of conjugation. To select 5 *Agrobacterium tumefaciens* harboring the vector, the incubated mixture for conjugation was spread on LB solid medium containing 50 mg/L of kanamycin and 30 mg/L of gentamicin and incubated for 2 days at 28°C. The selected *Agrobacterium tumefaciens* containing desired gene was inoculated into super broth (BHI medium, pH 5.6), 10 incubated for 2 days at 28°C and used for infection of plant.

ii) Transformation of *Cucumis melo*

The seeds of *Cucumis melo* sterilized were seeded for obtaining cotyledons. The cotyledons were collected in a manner that their 15 growth points were completely removed. *Agrobacterium tumefaciens* transformed with pRD400-tshr or pRD400-tshr-ecd was incubated for 18 hr at 28°C in super broth containing 100 µM acetosyringone (37 g/l brain heart infusion broth(Difco) and 0.2% sucrose, pH 5.6), and then the resulting medium was diluted 20-fold with inoculation 20 medium. The above inoculation medium (pH 5.6) contains MSB5 (Murashige & Skoog medium including Gamborg B5 vitamins), 3.0% sucrose, 0.5 g/L of MES [2-(N-Morpholino)ethanesulfonic acid Monohydrate], 6.0 mg/L of kinetin, 1.5 mg/L of IAA (indole-3-acetic acid), 1.0 mg/L of CuSO<sub>4</sub> · 5H<sub>2</sub>O, 100 µM acetosyringone and 25 5% DMSO.

Thereafter, the cotyledon was immersed in 40 ml of the

inoculation medium and incubated for 20 min. Then, the cotyledon was transferred to a coculturing medium (MSB5, 3.0% sucrose, 0.5 g/L of MES, 6.0 mg/L of kinetin, 1.5 mg/L of IAA, 1.0 mg/L of  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 0.6% agar, 100  $\mu\text{M}$  acetosyringone and 5% DMSO). The  
5 cotyledon was then cocultured under dark culture condition ( $26 \pm 1^\circ\text{C}$ , 24 hrs night) for 3 days. After coculturing, the cotyledon was placed on a selection medium (MSB5, 3.0% sucrose, 0.5 g/L of MES, 6.0 mg/L of kinetin, 1.5 mg/L of IAA, 1.0 mg/L of  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 0.6% agar, 100 mg/L of kanamycin and 500 mg/L of carbenicillin, pH  
10 5.6) and light-cultured at  $26 \pm 1^\circ\text{C}$  and 4,000 lux under 16 hr light condition for 3 days to induce generation of shoots.

The elongated shoots were transferred to a rooting medium (MSB5, 3.0% sucrose, 0.5 g/L of MES, 0.1 mg/L of NAA ( $\alpha$ -naphthalene acetic acid), 1.0 mg/L of  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 0.6% agar, 100 mg/L of kanamycin  
15 and 500 mg/L of carbenicillin, pH 5.6) and cultured for 2 weeks. The shoots with roots, which were considered to be transformed, were selected.

### iii) Transformation of *Curcumis sativa*

20 The seeds of *Curcumis sativa* sterilized were seeded for obtaining cotyledons. The cotyledons were collected in a manner that their growth points were completely removed. *Agrobacterium tumefaciens* transformed with pRD400-tshr or pRD400-tshr-ecd was incubated in the same manner as described in i). The sections of  
25 the cotyledon were immersed for 10 min in the inoculation medium containing *Agrobacterium* in the same manner as described in ii).

Thereafter, the cotyledon was cultured in a coculturing medium (MSB5 containing 2 mg/L of BAP and 0.01 mg/L of NAA) under light culture condition at 26°C for 2 days and then was cocultured with *Agrobacterium tumefaciens* at 4°C for 4 days. After coculturing, the cotyledon was placed on a selection medium containing MSB5, 3.0% sucrose, 0.5 g/L of MES, 0.4% phytigel, 2 mg/L of BAP, 0.01 mg/L of NAA, 500 mg/L of carbenicillin and 100 mg/L of kanamycin and cultured at 26±1°C and 8,000 lux under 16 hr light/8 hr dark condition.

Then, the regenerated shoots were transferred to a rooting medium (containing 0.01 mg/L of NAA, 100 mg/L of kanamycin and 0.4% agar) and cultured at 26±1°C and 8,000 lux under 16 hr light/8 hr dark condition. The shoots with roots considered to be transformed were analyzed by the method described in Example below.

iv) Transformation of *Citrullus vulgaris*

The seeds of *Citrullus vulgaris* sterilized were seeded for obtaining cotyledons. The cotyledons were collected in a manner that their growth points were completely removed. *Agrobacterium tumefaciens* transformed with pRD400-tshr or pRD400-tshr-ecd was incubated in the same manner as described in i). The cotyledon was immersed for 10 min in the inoculation medium containing *Agrobacterium* in the same manner as described in ii). Thereafter, the cotyledon was placed on a coculturing medium (4.04 g/L of MSB5, 3.0% sucrose, 0.5 g/L of MES and 0.6% agar, pH 5.6) and cultured under 16-hour light culture condition at 25±1°C and 4,000 lux for

2 days. Cultured cotyledon was placed on the medium (MSB5, 2 mg/L of BAP, 3.0% sucrose, 0.5 g/L of MES, 0.4% phytigel, 500 mg/L of carbenicillin and 200 mg/L of kanamycin, pH 5.6) and cultured at 25°C±1°C for 7 days. Following the incubation for 4 weeks, the  
5 shoots were selected.

v) Transformation of *Brassica campestris*

The seeds of *Brassica campestris* sterilized were seeded for obtaining petiole. The petioles were collected in a manner that  
10 their growth points were completely removed. *Agrobacterium tumefaciens* transformed with pRD400-tshr or pRD400-tshr-ecd was incubated in the same manner as described in i). The petiole was immersed for 10 min in the inoculation solution containing *Agrobacterium* in the same manner as described in ii). Thereafter,  
15 the petiole was cultured in a coculturing medium (MSB5, 3% sucrose, 1mg/L of 2,4-D and 6.5 g/L of agar power, pH 5.8) at 25°C for 2 days and subsequently at 4°C for 4 days.

To select the transformed *Brassica campestris*, the petiole was transferred to a selection medium (MSB5, 3% sucrose, 5 g/L of MES, 2 mg/L of BAP, 0.01 mg/L of NAA, 20 mg/L of kanamycin, 500 mg/L of  
20 Psedopen and 6.5 g/L of agar power, pH 5.8) and cultured at 25°C for 2 weeks under 16-hr light/8-hr dark condition. Two weeks after, The root for shoot was induced in a rooting medium (pH 5.8) containing MSB5, 3.0% sucrose, 5 g/L of MES, 0.1 mg/L of NAA, 20  
25 mg/L of kanamycin 500 mg/L of Pseudopen and 6.5 g/L of agar.

vi) Transformation of *Nicotiana tabacum*

The sterilized seeds of *Nicotiana tabacum* were seeded and

cultivated in sterilized condition over 2 weeks for obtaining young leaves. *Agrobacterium tumefaciens* transformed with pRD400-*tshr* or pRD400-*tshr-ecd* was incubated in the same manner as described in i of Example 2 and then mixed with the inoculation medium as in ii of Example 2. The fragments of young leaf with a size of 0.5-1 cm<sup>2</sup> were immersed for 10-15 min in the inoculation medium and then transferred to a coculturing medium (MSB5, 3.0% sucrose, 0.5 g/L of MES, 1.0 mg/L of BAP, 0.1 mg/L of NAA and 0.6% agar, pH 5.8).

The fragment was cocultured under dark culture condition (26±1°C, 24 hrs night) for 2 days. After coculturing, in order to form shoots by regeneration, the fragment was placed on a selection medium (MSB5, 3.0% sucrose, 0.5 g/L of MES, 1.0 mg/L of BAP, 0.1 mg/L of NAA, 0.6% agar, 100 mg/L of kanamycin and 500 mg/L of carbenicillin, pH 5.6) and cultured at 26±1°C and 4,000 lux for 2 weeks under 16-hr light condition. The elongated shoots were transferred to a rooting medium (MSB5, 3.0% sucrose, 0.5 g/L of MES, 0.01 mg/L of NAA, 0.6% agar, 100 mg/L of kanamycin and 500 mg/L of carbenicillin, pH 5.6) and cultured for 2 weeks. The shoots with roots, which were considered to be transformed, were selected.

### EXAMPLE III: Verification on Transformation of Plant by PCR

The transformants in Example II were verified as described below:

Using 10 mg of the shoots that were selected to be transformed, a genomic DNA for PCR analysis was obtained according to the

method described by Edwards K., et al. (*Nucleic Acids Research*, 19: 1349(1991)) and then PCR analysis was performed.

The primer set for PCR analysis of plant transformed with pRD400-*tshr* is corresponding to nucleotide sequence of *tshr* gene:  
5 forward primer, 5'-AAGGATCCC ATG AGG CCG GCG GAC-3'; and reverse  
primer, 5'-ATGGATCC TTA CAA AAC CGT TTG CAT-3'.

The primer set for PCR analysis of plant transformed with pRD400-*tshr-ecd* is corresponding to nucleotide sequence of *tshr-ecd* gene: forward primer, 5'-AAGGATCCC ATG AGG CCG GCG GAC-3'; and  
10 reverse primer, 5'-ATGGATCC TTA GCC CAT TAT GTC TTC-3'.

The PCR amplification was conducted using Taq polymerase according to the following thermal conditions: pre-denaturation at 96°C for 2 min followed by 35 cycles of annealing at 55°C for 1 min, extension at 72°C for 2 min and denaturation at 94°C for 1 min;  
15 followed by final extension at 72°C for 10 min. Amplified products were analyzed by electrophoresis on 1.0% agarose gel.

In Fig. 4, lane M shows 1 kb ladder, lane 1 represents PCR product of positive standard plasmid containing gene, pRD400-*tshr*, lane 2 represents PCR product of wild-type *Nicotiana tabacum* and  
20 lanes 3,4,5,6 and 7 represent PCR products of selected *Brassica campestris*, *Nicotiana tabacum*, *Cucumis melo*, *Citrullus vulgaris* and *Curcumis sativa*, respectively. As shown in Fig. 4, the band corresponding to *tshr* gene (2.3 kb) is observed in each lane, which indicated the successful transformation of plant in Example  
25 described above.

In Fig. 5, lane M shows 1 kb ladder, lane 1 represents PCR

products of positive standard plasmid containing gene, pRD400-  
tshr-ecd, lane 2 represents PCR product of wild-type *Nicotiana*  
*tabacum* and lanes 3,4,5,6 and 7 represent PCR products of selected  
*Brassica campestris*, *Nicotiana tabacum*, *Cucumis melo*, *Citrullus*  
5 *vulgaris* and *Curcumis sativa*, respectively. As shown in Fig. 5,  
the band corresponding to tshr-ecd gene (1.3 kb) is observed in  
each lane, which indicated the successful transformation of plant  
in above Example.

10 **EXAMPLE IV: Verification of TSHR or TSHR-ECD in Plant Transformants  
by Western Blotting**

2.5 ml of extraction buffer pre-prepared (5 ml of 100 mM Tris-  
Cl, pH 7.5, 40  $\mu$ l of 500 mM EDTA, pH 8.0, 1.5 ml of 1 mg/ml  
leupeptin, 600  $\mu$ l of 5 mg/ml BSA, 3 ml of 1 mg/ml DTT and 50  $\mu$ l of  
15 30 mg/ml PMSF (stock solution; 0.003 g PMSF in 10  $\mu$ l IPA) added  
just before use) were added to 1 g of the chopped leaves of  
transformants and then the leaves were ground finely in a mortar.  
The extract was centrifuged at 12,000 rpm and 4°C for 30 min, the  
supernatant was transferred to a new tube and stored on ice. The  
20 quantification of proteins in plant transformants was performed in  
accordance with Bradford method in a manner that dye (protein  
assay kit, Bio-Rad) was added to the extract and the absorbance at  
595 nm was measured with UV-spectrophotometer, followed by  
determining the protein amount with reference to the standard  
25 curve of bovine serum albumin. Then, the supernatant samples with  
the same amount were electrophoresed on 8% polyacrylamide gel

The protein band appearing by polyacrylamide gel electrophoresis was transferred to PVDF membrane and then the primary antibody (anti TSHR-rabbit, 1:1000 dilution, Santa Cruz Biotechnology, INC) was added to PVDF membrane and incubated for 1  
5 hr. After incubation, the membrane was washed and incubated with the secondary antibody (rabbit-goat HRP, 1:1000 dilution, Santa Cruz Biotechnology, INC) for 1 hr and washed. Then, the color development was allowed with 4-chloro-1-naphtol (4-CN). The bands showing the expected size of TSHR, i.e., about 76 kDa were  
10 observed, so that the existence of TSHR in transformants was verified (see Fig. 6).

**EXAMPLE V: Analysis of TSHR and TSHR-ECD Expressed in Plant Transformants by ELISA**

15 One ml of pre-prepared PBS (20 mM potassium phosphate, 150 mM NaCl pH 7.4) was added to 1 g of the chopped leaves of transformants and the leaves were ground finely in a mortar. The extract was centrifuged at 10,000 rpm and 4°C over 5 min, the supernatant was transferred to a new tube and stored on ice. 50 µl  
20 of PBS was added to each of 96 wells in a ELISA plate. As shown in Fig 7, the extract of wild-type *Nicotiana tabacum* as a negative control and the extracts of *Brassica campestris*, *Nicotiana tabacum*, *Cucumis melo*, *Citrullus vulgaris* and *Curcumis sativa* which were transformed with pRD400-*tshr* or pRD400-*tshr-ecd* were added to the  
25 corresponding wells in the ELISA plate and allowed to be coated on well in moisture chamber at 4°C

Each of coated wells in plate was washed 4-5 times with 200 µl

of washing buffer (PBS + 0.2% Tween20) and then 50  $\mu\text{l}$  of dilution buffer (washing buffer + 5% skim milk) at 4°C was added, followed by incubation in moisture chamber for blocking at 37°C for 1 hr. After blocking, each well was washed with 200  $\mu\text{l}$  of washing buffer 4-5 times. Serum of Grave's disease patient was serially diluted to 1/100, 1/200, 1/400, 1/800, 1/1600, 1/3200, 1/6400 and 1/12800 and 50  $\mu\text{l}$  of the dilute of each concentration was added to from lanes A to H as in Fig 7 and allowed to stand at 4°C for 2 hrs. As above, each of coated wells in plate was washed with 200  $\mu\text{l}$  of washing buffer and 300  $\mu\text{l}$  of blocking buffer (PBS buffer + 1% BBA, 5% sucrose and 0.05%  $\text{NaN}_3$ ) at 4°C was added, followed by incubated in moisture chamber for blocking at 4°C for 1 hr. After blocking, each well was washed with 200  $\mu\text{l}$  of washing buffer three times. Ten  $\mu\text{l}$  of diluted IgG conjugate (peroxidase labeling, 1/1000 dilution) were added and allowed to stand at 4°C for 1 hr.

Thereafter, the wells were washed with washing buffer and ABST peroxidase substrate (KPL corp. U.S.A.) was added, followed by incubation for 30 min. The reaction was stopped with 50  $\mu\text{l}$  of the stop buffer. The absorbance at 405 nm was measured with ELISA reader (TECAN sunrise). The result of analysis of recombinant proteins expressed in plants transformed with *tshr* gene, as shown in Fig 7, shows clear reaction even in about 1/5000-diluted samples, demonstrating that the functional TSHRs were expressed in plant transformants.

25

As described above, the present invention provides a method for preparing transformed plants expressing thyroid stimulating

hormone receptor (hTSHR) or thyroid stimulating hormone receptor-extracellular domain (hTSHR-ECD) and transformed plants. In addition, the present invention provides a method for preparing hTSHR or hTSHR-ECD from the transformed plants. As the present  
5 invention utilizes eucaryote-expression systems, the final products, hTSHR or hTSHR-ECD, are very likely to be secondarily modified and the convenient cultivation of transformed plants will allow for the mass production of human autoantigen, hTSHR or hTSHR-ECD.

What is claimed is:

1. A method for preparing transformed plants expressing thyroid stimulating hormone receptor (hTSHR) or thyroid stimulating hormone receptor-extracellular domain (hTSHR-ECD), which comprises  
5 the steps of:

(a) transforming plant cells with the following polynucleotide sequences: (i) a polynucleotide sequence encoding hTSHR or hTSHR-ECD; (ii) a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the  
10 polynucleotide sequence of (i); and (iii) a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of said RNA molecule;

(b) selecting transformed plant cells; and

(c) obtaining transformed plant by regenerating said  
15 transformed plant cells.

2. The method according to claim 1, wherein said plant is *Nicotiana tabacum*, *Cucumis melo*, *Curcumis sativa*, *Citrullus vulgaris* or *Brassica campestris*.  
20

3. The method according to claim 1, wherein said transformation is performed with an *Agrobacterium* transformation system.

4. The method according to claim 3, wherein the *Agrobacterium* transformation system is an *Agrobacterium tumefaciens*-binary vector system.  
25

5. The method according to claim 1 further comprising recovering

hTSHR or hTHSR-ECD from the regenerated transformed plant.

6. A transformed plant prepared by the method of any one of claims 1 to 5 which expresses hTSHR or hTHSR-ECD.

5

7. A method for preparing thyroid stimulating hormone receptor (hTSHR) or thyroid stimulating hormone receptor-extracellular domain (hTSHR-ECD), which comprises the steps of:

(a) transforming plant cells with the following polynucleotide sequences: (i) a polynucleotide sequence encoding hTSHR or hTSHR-ECD; (ii) a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the polynucleotide sequence of (i); and (iii) a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of said RNA molecule;

(b) selecting transformed plant cells;

(c) obtaining transformed plant by regenerating said transformed plant cells; and

(d) recovering hTSHR or hTHSR-ECD from said transformed plant.

20

8. The method according to claim 7, wherein said plant is *Nicotiana tabacum*, *Cucumis melo*, *Curcumis sativa*, *Citrullus vulgaris* or *Brassica campestris*.

25

9. The method according to claim 7, wherein the transformation is performed with an *Agrobacterium* transformation system.

10. The method according to claim 9, wherein said *Agrobacterim* transformation system is an *Agrobacterium tumefaciens*-binary vector system.

1/7

Fig.1




2/7

Fig. 2




Fig. 3



4/7

Fig. 4



5/7

Fig. 5






Fig. 6



1 : TSHR expressed in CHO cell line  
2 : Wild type *Nicotiana tabacum*  
3-4 : TSHR expressed in the transformed  
*Nicotiana tabacum*

7/7

Fig. 7



A1-H1: Wild type *Nicotiana tabacum*, A7-H7: PBS  
 A2-H2, A8-H8: transformed *Brassica campestris*  
 A3-H3, A9-H9: transformed *Nicotiana tabacum*  
 A4-H4, A10-H10: transformed *Cucumis melo*  
 A5-H5, A11-H11: transformed *Curcumis sativa*  
 A6-H6, A12-H12: transformed *Citrullus vulgaris*

# Sequence Listing

<110> NEXGEN BIOTECHNOLOGIES, INC.

<120> Production of Transformed Plants Expressing Thyroid Stimulating Hormone Receptor

<150> KR2002-38064

<151> 2002-07-02

<160> 2

<170> KopatentIn 1.71

<210> 1

<211> 2292

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1) .. (2289)

<400> 1

atg agg ccg gcg gac ttg ctg cag ctg gtg ctg ctg ctc gac ctg ccc 48

Met Arg Pro Ala Asp Leu Leu Gln Leu Val Leu Leu Leu Asp Leu Pro

1 5 10 15

agg gac ctg ggc gga atg ggg tgt tgc tct cca ccc tgc gag tgc cat 96

Arg Asp Leu Gly Gly Met Gly Cys Ser Ser Pro Pro Cys Glu Cys His

20 25 30

cag gag gag gac ttc aga gtc acc tgc aag gat att caa cgc atc ccc 144

Gln Glu Glu Asp Phe Arg Val Thr Cys Lys Asp Ile Gln Arg Ile Pro

35 40 45

agc tta ccg ccc agt acg cag act ctg aag ctt att gag act cac ctg 192

Ser Leu Pro Pro Ser Thr Gln Thr Leu Lys Leu Ile Glu Thr His Leu

50 55 60

aga act att cca agt cat gca ttt tct aat ctg ccc aat att tcc aga 240

Arg Thr Ile Pro Ser His Ala Phe Ser Asn Leu Pro Asn Ile Ser Arg

# Sequence Listing

65	70	75	80	
atc tac gta tct ata gat gtg act ctg cag cag ctg gaa tca cac tcc				288
Ile Tyr Val Ser Ile Asp Val Thr Leu Gln Gln Leu Glu Ser His Ser				
	85	90	95	
ttc tac aat ttg agt aaa gtg act cac ata gaa att cgg aat acc agg				336
Phe Tyr Asn Leu Ser Lys Val Thr His Ile Glu Ile Arg Asn Thr Arg				
	100	105	110	
aac tta act tac ata gac cct gat gcc ctc aaa gag ctc ccc ctc cta				384
Asn Leu Thr Tyr Ile Asp Pro Asp Ala Leu Lys Glu Leu Pro Leu Leu				
	115	120	125	
aag tcc ttg gca ttt tca aac act gga ctt aaa atg ttc cct gac ctg				432
Lys Ser Leu Ala Phe Ser Asn Thr Gly Leu Lys Met Phe Pro Asp Leu				
	130	135	140	
acc aaa gtt tat tcc act gat ata ttc ttt ata ctt gaa att aca gac				480
Thr Lys Val Tyr Ser Thr Asp Ile Phe Phe Ile Leu Glu Ile Thr Asp				
	145	150	155	160
aac cct tac atg acg tca atc cct gtg aat gct ttt cag gga cta tgc				528
Asn Pro Tyr Met Thr Ser Ile Pro Val Asn Ala Phe Gln Gly Leu Cys				
	165	170	175	
aat gaa acc ttg aca ctg aag ctg tac aac aat ggc ttt act tca gtc				576
Asn Glu Thr Leu Thr Leu Lys Leu Tyr Asn Asn Gly Phe Thr Ser Val				
	180	185	190	
caa gga tat gat ttc ttt ggg aca aag ctg gat gct gtt tac cta aac				624
Gln Gly Tyr Asp Phe Phe Gly Thr Lys Leu Asp Ala Val Tyr Leu Asn				
	195	200	205	
aag aat aaa tac ctg aca gtt att gac aaa gat gca ttt gga gga gta				672
Lys Asn Lys Tyr Leu Thr Val Ile Asp Lys Asp Ala Phe Gly Gly Val				
	210	215	220	
tac agt gga cca agc ttg ctg gac gtg tct caa acc agt gtc act gcc				720
Tyr Ser Gly Pro Ser Leu Leu Asp Val Ser Gln Thr Ser Val Thr Ala				

# Sequence Listing

225	230	235	240	
ctt cca tcc aaa ggc ctg gag cac ctg aag gaa ctg ata gca aga aac				768
Leu Pro Ser Lys Gly Leu Glu His Leu Lys Glu Leu Ile Ala Arg Asn				
245	250	255		
agc tgg act ctt aag aaa ctt gca ctt tcc ttg agt ttc ctt cac ctc				816
Ser Trp Thr Leu Lys Lys Leu Ala Leu Ser Leu Ser Phe Leu His Leu				
260	265	270		
aca cgg gct gac ctt tct tac cca agc cac tgc tgt gct ttt aag aat				864
Thr Arg Ala Asp Leu Ser Tyr Pro Ser His Cys Cys Ala Phe Lys Asn				
275	280	285		
cag aag aaa atc aga gga atc ctt gag tcc ttg atg tgt aat gag agc				912
Gln Lys Lys Ile Arg Gly Ile Leu Glu Ser Leu Met Cys Asn Glu Ser				
290	295	300		
agt atc gag acg ttg cgc cag aga aaa tct gtg aat gcc ttg aat agc				960
Ser Ile Glu Thr Leu Arg Gln Arg Lys Ser Val Asn Ala Leu Asn Ser				
305	310	315	320	
ccc ctc cac cag gaa tat gaa gag aat ctg ggt gac agc att gtt ggg				1008
Pro Leu His Gln Glu Tyr Glu Glu Asn Leu Gly Asp Ser Ile Val Gly				
325	330	335		
tac aag gaa aag tcc aag ttc cag gat act cat aac aac gct cat tat				1056
Tyr Lys Glu Lys Ser Lys Phe Gln Asp Thr His Asn Asn Ala His Tyr				
340	345	350		
tac gtc ttc ttt gaa gaa caa gag gat gag atc att ggt ttt ggc cag				1104
Tyr Val Phe Phe Glu Glu Gln Glu Asp Glu Ile Ile Gly Phe Gly Gln				
355	360	365		
gag ctc aaa aac ccc cag gaa gag act cta caa gct ttt gac agc cat				1152
Glu Leu Lys Asn Pro Gln Glu Glu Thr Leu Gln Ala Phe Asp Ser His				
370	375	380		
tat gac tac acc ata tgt ggg gac agt gaa gac atg gtg tgt acc ccc				1200
Tyr Asp Tyr Thr Ile Cys Gly Asp Ser Glu Asp Met Val Cys Thr Pro				

# Sequence Listing

385	390	395	400	
aag tcc gat gag ttc aac ccg tgt gaa gac ata atg ggc tac aag ttc				1248
Lys Ser Asp Glu Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Lys Phe				
405	410	415		
ctg aga att gtg gtg tgg ttc gtt agt ctg ctg gct ctc ctg ggc aat				1296
Leu Arg Ile Val Val Trp Phe Val Ser Leu Leu Ala Leu Leu Gly Asn				
420	425	430		
gtc ttt gtc ctg ctt att ctc ctc acc agc cac tac aaa ctg aac gtc				1344
Val Phe Val Leu Leu Ile Leu Leu Thr Ser His Tyr Lys Leu Asn Val				
435	440	445		
ccc cgc ttt ctc atg tgc aac ctg gcc ttt gcg gat ttc tgc atg ggg				1392
Pro Arg Phe Leu Met Cys Asn Leu Ala Phe Ala Asp Phe Cys Met Gly				
450	455	460		
atg tac ctg ctc ctc atc gcc tct gta gac ctc tac act cac tct gag				1440
Met Tyr Leu Leu Leu Ile Ala Ser Val Asp Leu Tyr Thr His Ser Glu				
465	470	475	480	
tac tac aac cat gcc atc gac tgg cag aca ggc cct ggg tgc aac acg				1488
Tyr Tyr Asn His Ala Ile Asp Trp Gln Thr Gly Pro Gly Cys Asn Thr				
485	490	495		
gct ggt ttc ttc act gtc ttt gca agc gag tta tcg gtg tat acg ctg				1536
Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu				
500	505	510		
acg gtc atc acc ctg gag cgc tgg tat gcc atc acc ttc gcc atg gcc				1584
Thr Val Ile Thr Leu Glu Arg Trp Tyr Ala Ile Thr Phe Ala Met Ala				
515	520	525		
ctg gac cgg aag atc cgc ctc agg cac gca tgt gcc atc atg gtt ggg				1632
Leu Asp Arg Lys Ile Arg Leu Arg His Ala Cys Ala Ile Met Val Gly				
530	535	540		
ggc tgg gtt tgc tgc ttc ctt ctc gcc ctg ctt cct ttg gtg gga ata				1680
Gly Trp Val Cys Cys Phe Leu Leu Ala Leu Leu Pro Leu Val Gly Ile				

# Sequence Listing

545	550	555	560	
agt agc tat gcc aaa gtc agt atc tgc ctg ccc atg gac acc gag acc				1728
Ser Ser Tyr Ala Lys Val Ser Ile Cys Leu Pro Met Asp Thr Glu Thr				
565	570	575		
cct ctt gct ctg gca tat att gtt ttt gtt ctg acg ctc aac ata gtt				1776
Pro Leu Ala Leu Ala Tyr Ile Val Phe Val Leu Thr Leu Asn Ile Val				
580	585	590		
gcc ttc gtc atc gtc tgc tgc tgt tat gtg aag atc tac atc aca gtc				1824
Ala Phe Val Ile Val Cys Cys Cys Tyr Val Lys Ile Tyr Ile Thr Val				
595	600	605		
cga aat ccg cac aac cca ggg gac aaa gat acc aaa att gcc aag agg				1872
Arg Asn Pro His Asn Pro Gly Asp Lys Asp Thr Lys Ile Ala Lys Arg				
610	615	620		
atg gct gtg ttg atc ttc acc gac ttc acg tgc atg gcc cca atc tca				1920
Met Ala Val Leu Ile Phe Thr Asp Phe Thr Cys Met Ala Pro Ile Ser				
625	630	635	640	
ttc tat gct gtg tca gca att ctg aac aag cct ctc atc act gtt agc				1968
Phe Tyr Ala Val Ser Ala Ile Leu Asn Lys Pro Leu Ile Thr Val Ser				
645	650	655		
aac tcc aaa atc ttg ctg gta ctc ttc tat cca att aac tcc tgt gcc				2016
Asn Ser Lys Ile Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala				
660	665	670		
aat cca ttc ctc tat gct att ttc acc aag gcc ttc cag agg gat gtg				2064
Asn Pro Phe Leu Tyr Ala Ile Phe Thr Lys Ala Phe Gln Arg Asp Val				
675	680	685		
ttc atc cta ctc agc aag ttt ggc atc tgt aaa cgc cag gct cag gca				2112
Phe Ile Leu Leu Ser Lys Phe Gly Ile Cys Lys Arg Gln Ala Gln Ala				
690	695	700		
tac cgg ggg cag agg gtt cct cca aag aac agc act gat att cag gtt				2160
Tyr Arg Gly Gln Arg Val Pro Pro Lys Asn Ser Thr Asp Ile Gln Val				

# Sequence Listing

```

705                710                715                720

caa aag gtt acc cac gac atg agg cag ggt ctc cac aac atg gaa gat      2208
Gln Lys Val Thr His Asp Met Arg Gln Gly Leu His Asn Met Glu Asp
                725                730                735

gtc tat gaa ctg att gaa aac tcc cat cta acc cca aag aag caa ggc      2256
Val Tyr Glu Leu Ile Glu Asn Ser His Leu Thr Pro Lys Lys Gln Gly
                740                745                750

caa atc tca gaa gag tat atg caa acg gtt ttg      t aa      2292
Gln Ile Ser Glu Glu Tyr Met Gln Thr Val Leu
                755                760

<210>  2
<211>  763
<212>  PRT
<213>  Homo sapiens

<400>  2
Met Arg Pro Ala Asp Leu Leu Gln Leu Val Leu Leu Leu Asp Leu Pro
  1                5                10                15

Arg Asp Leu Gly Gly Met Gly Cys Ser Ser Pro Pro Cys Glu Cys His
  20                25                30

Gln Glu Glu Asp Phe Arg Val Thr Cys Lys Asp Ile Gln Arg Ile Pro
  35                40                45

Ser Leu Pro Pro Ser Thr Gln Thr Leu Lys Leu Ile Glu Thr His Leu
  50                55                60

Arg Thr Ile Pro Ser His Ala Phe Ser Asn Leu Pro Asn Ile Ser Arg
  65                70                75                80

Ile Tyr Val Ser Ile Asp Val Thr Leu Gln Gln Leu Glu Ser His Ser
  85                90                95

Phe Tyr Asn Leu Ser Lys Val Thr His Ile Glu Ile Arg Asn Thr Arg

```

# Sequence Listing

100	105	110
Asn Leu Thr Tyr Ile Asp Pro Asp Ala Leu Lys Glu Leu Pro Leu Leu		
115	120	125
Lys Ser Leu Ala Phe Ser Asn Thr Gly Leu Lys Met Phe Pro Asp Leu		
130	135	140
Thr Lys Val Tyr Ser Thr Asp Ile Phe Phe Ile Leu Glu Ile Thr Asp		
145	150	155
		160
Asn Pro Tyr Met Thr Ser Ile Pro Val Asn Ala Phe Gln Gly Leu Cys		
165	170	175
Asn Glu Thr Leu Thr Leu Lys Leu Tyr Asn Asn Gly Phe Thr Ser Val		
180	185	190
Gln Gly Tyr Asp Phe Phe Gly Thr Lys Leu Asp Ala Val Tyr Leu Asn		
195	200	205
Lys Asn Lys Tyr Leu Thr Val Ile Asp Lys Asp Ala Phe Gly Gly Val		
210	215	220
Tyr Ser Gly Pro Ser Leu Leu Asp Val Ser Gln Thr Ser Val Thr Ala		
225	230	235
		240
Leu Pro Ser Lys Gly Leu Glu His Leu Lys Glu Leu Ile Ala Arg Asn		
245	250	255
Ser Trp Thr Leu Lys Lys Leu Ala Leu Ser Leu Ser Phe Leu His Leu		
260	265	270
Thr Arg Ala Asp Leu Ser Tyr Pro Ser His Cys Cys Ala Phe Lys Asn		
275	280	285
Gln Lys Lys Ile Arg Gly Ile Leu Glu Ser Leu Met Cys Asn Glu Ser		
290	295	300
Ser Ile Glu Thr Leu Arg Gln Arg Lys Ser Val Asn Ala Leu Asn Ser		
305	310	315
		320

# Sequence Listing

Pro Leu His Gln Glu Tyr Glu Glu Asn Leu Gly Asp Ser Ile Val Gly  
 325 330 335

Tyr Lys Glu Lys Ser Lys Phe Gln Asp Thr His Asn Asn Ala His Tyr  
 340 345 350

Tyr Val Phe Phe Glu Glu Gln Glu Asp Glu Ile Ile Gly Phe Gly Gln  
 355 360 365

Glu Leu Lys Asn Pro Gln Glu Glu Thr Leu Gln Ala Phe Asp Ser His  
 370 375 380

Tyr Asp Tyr Thr Ile Cys Gly Asp Ser Glu Asp Met Val Cys Thr Pro  
 385 390 395 400

Lys Ser Asp Glu Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Lys Phe  
 405 410 415

Leu Arg Ile Val Val Trp Phe Val Ser Leu Leu Ala Leu Leu Gly Asn  
 420 425 430

Val Phe Val Leu Leu Ile Leu Leu Thr Ser His Tyr Lys Leu Asn Val  
 435 440 445

Pro Arg Phe Leu Met Cys Asn Leu Ala Phe Ala Asp Phe Cys Met Gly  
 450 455 460

Met Tyr Leu Leu Leu Ile Ala Ser Val Asp Leu Tyr Thr His Ser Glu  
 465 470 475 480

Tyr Tyr Asn His Ala Ile Asp Trp Gln Thr Gly Pro Gly Cys Asn Thr  
 485 490 495

Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu  
 500 505 510

Thr Val Ile Thr Leu Glu Arg Trp Tyr Ala Ile Thr Phe Ala Met Ala  
 515 520 525

# Sequence Listing

Leu Asp Arg Lys Ile Arg Leu Arg His Ala Cys Ala Ile Met Val Gly  
530 535 540

Gly Trp Val Cys Cys Phe Leu Leu Ala Leu Leu Pro Leu Val Gly Ile  
545 550 555 560

Ser Ser Tyr Ala Lys Val Ser Ile Cys Leu Pro Met Asp Thr Glu Thr  
565 570 575

Pro Leu Ala Leu Ala Tyr Ile Val Phe Val Leu Thr Leu Asn Ile Val  
580 585 590

Ala Phe Val Ile Val Cys Cys Cys Tyr Val Lys Ile Tyr Ile Thr Val  
595 600 605

Arg Asn Pro His Asn Pro Gly Asp Lys Asp Thr Lys Ile Ala Lys Arg  
610 615 620

Met Ala Val Leu Ile Phe Thr Asp Phe Thr Cys Met Ala Pro Ile Ser  
625 630 635 640

Phe Tyr Ala Val Ser Ala Ile Leu Asn Lys Pro Leu Ile Thr Val Ser  
645 650 655

Asn Ser Lys Ile Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala  
660 665 670

Asn Pro Phe Leu Tyr Ala Ile Phe Thr Lys Ala Phe Gln Arg Asp Val  
675 680 685

Phe Ile Leu Leu Ser Lys Phe Gly Ile Cys Lys Arg Gln Ala Gln Ala  
690 695 700

Tyr Arg Gly Gln Arg Val Pro Pro Lys Asn Ser Thr Asp Ile Gln Val  
705 710 715 720

Gln Lys Val Thr His Asp Met Arg Gln Gly Leu His Asn Met Glu Asp  
725 730 735

Val Tyr Glu Leu Ile Glu Asn Ser His Leu Thr Pro Lys Lys Gln Gly

# Sequence Listing

---

740

745

750

Gln Ile Ser Glu Glu Tyr Met Gln Thr Val Leu

755

760

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR03/01308

## A. CLASSIFICATION OF SUBJECT MATTER

**IPC7 C07K 14/59**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 : C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
Korean Patents and Applications for Inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
PubMed, CA, Delphion

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Stiens, L. R., et al. "Development of serum-free bioreactor production of recombinant human thyroid stimulating hormone receptor" Biotechnology Progress, 2000, Vol. 16(5): pages 703-709. See the abstract.	1-10
A	Mullins R. J., et al. "Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines" Journal of Clinical Investigation, 1995, Vol. 96(1): pages 30-37. See the abstract.	1-10
A	EP 0719858A2 (Takao et al.), Mar. 07, 1996, See the whole document.	1-10

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 NOVEMBER 2003 (19.11.2003)

Date of mailing of the international search report

19 NOVEMBER 2003 (19.11.2003)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office  
920 Dunsan-dong, Seo-gu, Daejeon 302-701,  
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

PARK, JEONG UNG

Telephone No. 82-42-481-8159



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR03/01308

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0719858A2 (Takao et al.)	Mar. 07, 1996	JP 8228769A2	Sep. 10, 1996